RecruitingPhase 2NCT07668388

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Efficacy and Safety of Once-weekly Subcutaneous UBT251 in Participants With Type 2 Diabetes - a Dose-finding Study

Sponsor

Novo Nordisk A/S

Enrollment

300 participants

Start Date

Jun 22, 2026

Study Type

INTERVENTIONAL

Conditions

Diabetes Mellitus, Type 2

Summary

The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatment participants get is decided by chance. UBT251 is the treatment being tested and is not yet available for doctors to prescribe, while semaglutide is a medicine used to treat type 2 diabetes that doctors can already prescribe.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Semaglutide, a drug called Semaglutide Placebo, and others for people with diabetes mellitus, type 2. The study is currently recruiting participants at 69 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGUBT251

UBT251 will be administered subcutaneously once-weekly.

DRUGUBT251 Placebo

UBT251 placebo will be administered subcutaneously once-weekly.

DRUGSemaglutide

Semaglutide will be administered subcutaneously once-weekly.

DRUGSemaglutide Placebo

Semaglutide placebo will be administered subcutaneously once-weekly.

Locations(69)

Flourish Research

Birmingham, Alabama, United States

Ark Clinical Research

Fountain Valley, California, United States

Ark Clinical Research

Long Beach, California, United States

Los Angeles Institute for Metabolic Research

Los Angeles, California, United States

Catalina Research Institute, LLC

Montclair, California, United States

Encore Medical Research LLC

Hollywood, Florida, United States

South Broward Research LLC

Miramar, Florida, United States

Encore Medical Research of Weston

Weston, Florida, United States

Midwest Inst For Clin Res

Indianapolis, Indiana, United States

Cotton O'Neil Diabetes & Endocrinology

Topeka, Kansas, United States

MD Medical Research

Oxon Hill, Maryland, United States

PharmQuest

Greensboro, North Carolina, United States

KDCILM, LLC & Accellacare US, Inc.

Wilmington, North Carolina, United States

Plains Clinical Research Center, LLC_Fargo

Fargo, North Dakota, United States

Preferred Primary Care Physicians, Inc.

Uniontown, Pennsylvania, United States

Monroe Biomedical Research, LLC

North Charleston, South Carolina, United States

LifeDoc Health

Memphis, Tennessee, United States

IMA Clinical Research

Austin, Texas, United States

Private Practice - Dr. Laila A. Hassan

Houston, Texas, United States

Radiance Clinical Research

Lampasas, Texas, United States

Quality Research Inc

San Antonio, Texas, United States

Tekton Research Inc

San Antonio, Texas, United States

Consano Clin Res-Shavano Park

Shavano Park, Texas, United States

Chrysalis Clinical Research

St. George, Utah, United States

The Vancouver Clinic

Vancouver, Washington, United States

Castle Hill Medical Centre

Castle Hill, New South Wales, Australia

Hunter Medical Research Institute - Endocrinology and Diabetes

New Lambton Heights, New South Wales, Australia

Roger Chih Yu Chen

Sydney, New South Wales, Australia

Royal Adelaide Hospital - Cardiology Department

Adelaide, South Australia, Australia

Baker Heart and Diabetes Institute

Melbourne, Victoria, Australia

Versdias - Diabetologikum Amberg

Amberg, Bavaria, Germany

Herz- und Diabeteszentrum NRW - Bad Oeynhausen

Bad Oeynhausen, Germany

Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR

Berlin, Germany

DSP Bochum, Diabetes- und Stoffwechselpraxis

Bochum, Germany

Studiengesellschaft Dres. Könemann/Steinmann GbR

Bünde, Germany

InnoDiab Forschung GmbH

Essen, Germany

Mesut Durmaz, Hof

Hof, Germany

CRS Clinical Research Mannheim GmbH (hVIVO Mannheim)

Mannheim, Germany

Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ

Szeged, Csongrád-Csanád, Hungary

Szent Margit Rendelőintézet Nonprofit Kft.

Budapest, Hungary

Semmelweis Egyetem

Budapest, Hungary

PVN Kutató Kft.

Budapest, Hungary

Pécsi Tudományegyetem ÁOK

Pécs, Hungary

1 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ

Lublin, Lublin Voivodeship, Poland

NZOZ Vita-Diabetica Malgorzata Buraczyk

Bialystok, Podlaskie Voivodeship, Poland

Uniwersytecki Szpital Kliniczny w Bialymstoku

Bialystok, Poland

Specjalistyczna Praktyka Lekarska Diabetologia, Leczenie Cukrzycy i Otyłości lek. Monika Piwowar

Kielce, Poland

Clinical Best Solutions Sp. z o.o., Sp. k

Lublin, Poland

Formed 2 Sp. z o.o.

Oświęcim, Poland

S.C. Top Diabet Srl

Craiova, Dolj, Romania

Mariodiab Clinic SRL

Brasov, Romania

SC Nutrilife SRL

Bucharest, Romania

S.C Milena Sante SRL

Galati, Romania

Clinica Korall S.R.L. Satu Mare

Satu Mare, Romania

Spitalul Clinic Judetean De Urgenta Pius Brinzeu Timisoara

Timișoara, Romania

MEDISPEKTRUM s.r.o.

Bratislava, Slovakia

IN-DIA s.r.o.

Lučenec, Slovakia

MEDI-DIA s.r.o.

Sabinov, Slovakia

ARETEUS s.r.o.

Trebišov, Slovakia

Chosun University Hospital_Endocrinology

Gwangju, South Korea

Asan Medical Center_Endocrinology

Seoul, South Korea

The Catholic University of Korea, Seoul ST. Mary's Hospital_Endocrinology

Seoul, South Korea

Korea University Guro Hospital_Endocrinology

Seoul, South Korea

Equip D'assistencia Primaria Vic S.L.P.

Vic, Barcelona, Spain

Hospital Vall d'Hebron

Barcelona, Spain

Eap Osona Sud Alt Congost S.L.P

Centelles (Barcelona), Spain

Hospital Universitario de la Princesa

Madrid, Spain

Hospital Universitario Marqués de Valdecilla

Santander, Spain

H. Infanta Luisa_Endocrino y Obesidad

Seville, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07668388

Related Trials

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

NCT0721555942 locations

Metabolic and Inflammatory Outcomes of the Ketogenic Diet Comparing Saturated and Unsaturated Fat Sources

NCT056814681 location

A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)

NCT072424695 locations

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

NCT06112418125 locations

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT070644731154 locations